Genetic risk factors and the anti atherosclerotic effect of pioglitazone on carotid atherosclerosis of subjects with type 2 diabetes-a retrospective study-

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 4, 2010, Pages 386-394

  Saitou, Miyoko ^a   Osonoi, Takeshi ^a   Kawamori, Ryuzo ^b   Katakami, Naoto ^c   Kaneto, Hideaki ^c   Matsuhisa, Munehide ^c   Yamasaki, Yoshimistu ^c  

^a Naka Kinen Clinics   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; IMT; Pioglitazone; Single nucleotide polymorphism

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE COURSE; DISEASE DURATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 77953512866     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.2527     Document Type: Article

References (36)

1. Chait A, Bierman EL: Pathogenesis of macrovascular disease in diabetesIn: Joslin's Diabetes Mellitused by Kahn CR, GCWeir GC, p648-664, Lea & Febiger, Philadel-phia, 1994
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339: 229-234
3. Yamasaki Y, Kawamori R, Matsushima H, Nishizawa H, Kodama M, Kajimoto Y, Morishima T, Kamada T: Ath-erosclerosis in carotid artery of young IDDM patients monitored by ultrasound highresolution B-mode imaging. Diabetes, 1994; 43: 634-639
4. Yamasaki Y, Katakami N, Sakamoto K, Kaneto H, Matsuhisa M, Sato H, Hori M, Haneda M, Kashiwagi A, Tanaka Y, Kawamori R, Kuno S: Combination of multiple genetic risk factors is synergistically associated with carotid atherosclerosis in Japanese subjects with type 2 diabetes. Diabetes Care, 2006; 29: 2445-2451
5. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Kahn MA, Perez AT, Jacober SJ, GLAI Study Investigators: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care, 2005; 28: 1547-1554
6. Haffner SM, Greenberg AS, Weston WM, Chen H, Wil-liams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 2002; 106: 679-684
7. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, Reilly MP, Chittams J, Rader DJ: Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol, 2006; 26: 182-188
8. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab, 2001; 86: 3452-3456
9. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, futzner AP: Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes melli- tus: results from a controlled randomized study. Circulation, 2005; 111: 2525-2531
10. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino Sr. RB, Perez A, Provost JC, Haffner SM: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA, 2006; 296: 2572-2581
11. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study:, PROspective pioglitAzone Clinical Trial In macroVascularEvents;:a randomised controlled trial. Lancet, 2005; 366: 1279-1289
12. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy JA; PROactive Investigators Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive:, PROspective pioglitAzone Clinical Trial In macroVascular Events 04. Stroke, 2007; 38: 865-873
13. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive:, PRO-active 05; Study. J Am Coll Cardiol, 2007; 49: 1772-1780
14. Kawamori R, Yamasaki Y, Matsushima H, Nishizawa H, Nao K, Hougaku H, Maeda H, Handa N, Matsumoto M, Kamada T: Prevalence of carotid atherosclerosis in diabetic patients Ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care, 1992; 15: 1290-1294
15. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R: Intimal plus medial thickness of the arterial wallA direct measurement with ultrasound imaging. Circulation, 1986; 74: 1399-1406
16. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med, 2002; 347: 1916-1923
17. Fujiwara S, Emoto M, Komatsu M, Notoyama K, Morioka T, Koyama H, Shoji T, Inaba M, Nishizawa Y: Arterial wall thickness is associated with insulin resistance in type 2 diabetic patients. J Atheroscler Thromb, 2003; 10: 246-252
18. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX: Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities:, ARIC; Study:, 1987-1993. Am J Epidemiol, 1997; 146: 483-494
19. Lee E, Emoto M, Teramura M, Tsuchikura S, Ueno H, Shinohara K, Morioka T, Mori K, Koyama H, Shoji T, Okuno Y, Inaba M, Nishizawa Y: The combination of IMT and stiffness parameter beta is highly associated with concurrent coronary artery disease in type 2 diabetes. J Atheroscler Thromb, 2009; 16: 33-39
20. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK: Cardiovascular Health Study Collaborative Research Group: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med, 1999; 340: 14-22
21. Lusis AJ, Fogelman AM, Fonarow GC: Genetic basis of atherosclerosis: Part II Clinical Implications. Circulation, 2004; 110: 2066-2071
22. Frost D, Pfohl M, Clemens P, Haring HU, Beischer W: Evaluation of the insertion/deletion ACE gene polymorphism as a risk factor for carotid artery intima-media thickening and hypertension in young type 1 diabetic patients. Diabetes Care, 1998; 21: 836-840
23. Mannami T, Katsuya T, Baba S, Inamoto N, Ishikawa K, Higaki J, Ogihara T, Ogata J: Low potentiality of angio-tensin-converting enzyme gene insertion/deletion poly-morphism as a useful predictive marker for carotid atherogenesis in a large general population of a Japanese city: the Suita study. Stroke, 2001; 32: 1250-1256
24. Kogawa K, Nishizawa Y, Hosoi M, Kawagishi T, Maekawa K, Shoji T, Okuno Y, Morii H: Effect of polymorphism of apolipoprotein E and angiotensin-converting enzyme genes on arterial wall thickness. Diabetes, 1997; 46: 682-687
25. Yamasaki Y, Tsujino T, Kodama M, Kajimoto Y: DD genotype of the ACE gene as an atherosclerosis-independent risk factor for myocardial infarction. Circulation, 1997; 96: 3782
26. Arai K, Yamasaki Y, Kajimoto Y, Watada H, Umayahara Y, Kodama M, Sakamoto K, Hori M: Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM. Diabetes, 1997; 46: 2102-2104
27. Yokoyama H, Katakami N, Yamasaki Y: Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke, 2006; 37: 2420-2427
28. Oyama T, Saiki A, Endoh K, Ban N, Nagayama D, Ohhira M, Koide N, Miyashita Y, Shirai K: Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intimamedia thickness in type 2 diabetes mellitus treated by sul-fonyurea. J Atheroscler Thromb 2008; 15: 154-159
29. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in angio-tensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest, 1990; 86: 1343-1346
30. Toba H, Miki S, Shimizu T, Yoshimura A, Inoue R, Sawai N, Tsukamoto R, Murakami M, Morita Y, Nakayama Y, Kobara M, Nakata T: The direct antioxidative and antiinflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozoto-cin-induced diabetic rat aorta. Eur J Pharmacol, 2006; 549: 124-132
31. Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC: Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem, 2003; 36: 431-441
32. Robinson K, Mayer EL, Miller DP, Green R, Fvan Lente:, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW: Hyperhomo-cysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation, 1995; 92: 2825-2830
33. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA, 1995; 274: 1049-1057
34. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, Genest Jr J, Rosen R: Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol, 1997; 17: 569-573
35. Hsueh WA, Law RE: PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol, 2001; 21: 1891-1895
36. Blaschke F, Spanheimer R, Khan M, Law RE: Vascular effects of TZDs: new implicationsVascul Pharmacol, 2006; 45: 3-18